You have read all your free articles, to continue reading subscribe to read the rest of this content.
Oncopeptides has, together with HealthCap and Industrifonden (together the “Main Shareholders”), decided to, in order to further the company’s continued development of its product candidate Ygalo, carry out a broadening of its shareholder base through a new share issue of SEK 650 million (the Already a subscriber Login You have…
Scandinavian Biopharma has entered into an agreement with Flynn Pharma for the viper antivenom ViperaTAb. Under the agreement, Scandinavian Biopharma will have exclusive rights to service and make ViperaTAb available for emergency use in the Nordics, Baltic States and Germany. “We are very pAlready a subscriber Login You have read…
Genmab and argenx have entered into a collaboration agreement to jointly discover, develop and commercialize novel therapeutic antibodies with applications in immunology, as well as in oncology therapeutic areas. The multiyear collaboration will leverage the antibody engineering expertise and knoAlready a subscriber Login You have read all your free articles,…
The US Food and Drug Administration (FDA) has approved the self-administration of Fasenra (benralizumab) in a pre-filled, single-use auto-injector (the Fasenra Pen). The approval is supported by data from the Phase III GRECO trial and the Phase I AMES trial. The safety and tolerability of FasenrAlready a subscriber Login You have…
